JP2023512782A - 抗ヘプシン抗体およびその使用 - Google Patents

抗ヘプシン抗体およびその使用 Download PDF

Info

Publication number
JP2023512782A
JP2023512782A JP2022547871A JP2022547871A JP2023512782A JP 2023512782 A JP2023512782 A JP 2023512782A JP 2022547871 A JP2022547871 A JP 2022547871A JP 2022547871 A JP2022547871 A JP 2022547871A JP 2023512782 A JP2023512782 A JP 2023512782A
Authority
JP
Japan
Prior art keywords
cdr
seq
antibody
hepsin
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022547871A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023512782A5 (enExample
Inventor
ブレイク ピー． ジョンソン，
ティモシー ジェイ． オブライエン，
Original Assignee
ナボー， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ナボー， インコーポレイテッド filed Critical ナボー， インコーポレイテッド
Publication of JP2023512782A publication Critical patent/JP2023512782A/ja
Publication of JP2023512782A5 publication Critical patent/JP2023512782A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2470/00—Immunochemical assays or immunoassays characterised by the reaction format or reaction type
    • G01N2470/04—Sandwich assay format

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022547871A 2020-02-05 2021-02-03 抗ヘプシン抗体およびその使用 Pending JP2023512782A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062970626P 2020-02-05 2020-02-05
US62/970,626 2020-02-05
PCT/US2021/016409 WO2021158660A2 (en) 2020-02-05 2021-02-03 Anti-hepsin antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2023512782A true JP2023512782A (ja) 2023-03-29
JP2023512782A5 JP2023512782A5 (enExample) 2024-01-31

Family

ID=77200525

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022547871A Pending JP2023512782A (ja) 2020-02-05 2021-02-03 抗ヘプシン抗体およびその使用

Country Status (11)

Country Link
US (1) US20230236192A1 (enExample)
EP (1) EP4100062A4 (enExample)
JP (1) JP2023512782A (enExample)
KR (1) KR20220137696A (enExample)
CN (1) CN115427075A (enExample)
AU (1) AU2021215999A1 (enExample)
BR (1) BR112022015523A2 (enExample)
CA (1) CA3169809A1 (enExample)
IL (1) IL295258A (enExample)
MX (1) MX2022009584A (enExample)
WO (1) WO2021158660A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025259819A1 (en) * 2024-06-11 2025-12-18 Navaux, Inc. Anti-hepsin antibodies and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011161189A1 (en) * 2010-06-24 2011-12-29 F. Hoffmann-La Roche Ag Anti-hepsin antibodies and methods of use
JP2013507966A (ja) * 2009-10-22 2013-03-07 ジェネンテック， インコーポレイテッド 抗ヘプシン抗体及びその使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007524605A (ja) * 2003-04-03 2007-08-30 ピーディーエル バイオファーマ，インコーポレイティド インテグリンα５β１のインヒビターおよび組織顆粒化の制御のためのそれらの使用
US20050025763A1 (en) * 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US7029675B1 (en) * 2003-06-04 2006-04-18 Shu-Wha Lin Hepsin antagonist and methods of use
US8383351B2 (en) * 2008-06-11 2013-02-26 Oxford Brookes University Antibody to inhibin/ activin β-B subunit
WO2010082034A1 (en) * 2009-01-16 2010-07-22 University Of Exeter Antibody
CN102093479B (zh) * 2010-11-29 2012-10-03 侯宗柳 抗人血管内皮生长因子受体2的重组嵌合抗体
EP2721417A4 (en) * 2011-06-17 2015-05-06 Univ Arkansas NEW MARKERS FOR EARLY DIAGNOSIS OF EGG CANCER, MONITORING DURING THE CORRESPONDING THERAPY AND NEW THERAPY OPTIONS DURING AND AFTER THE CORRESPONDING CHEMOTHERAPY
US20180305702A1 (en) * 2015-09-15 2018-10-25 Advaxis, Inc. Listeria-Based Immunogenic Compositions And Methods Of Use Thereof in Cancer Prevention And Treatment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013507966A (ja) * 2009-10-22 2013-03-07 ジェネンテック， インコーポレイテッド 抗ヘプシン抗体及びその使用方法
WO2011161189A1 (en) * 2010-06-24 2011-12-29 F. Hoffmann-La Roche Ag Anti-hepsin antibodies and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 284, no. 35, JPN6024053245, 2009, pages 23177 - 23181, ISSN: 0005674816 *

Also Published As

Publication number Publication date
WO2021158660A2 (en) 2021-08-12
KR20220137696A (ko) 2022-10-12
BR112022015523A2 (pt) 2022-09-27
EP4100062A2 (en) 2022-12-14
CN115427075A (zh) 2022-12-02
MX2022009584A (es) 2022-10-07
US20230236192A1 (en) 2023-07-27
AU2021215999A1 (en) 2022-09-01
CA3169809A1 (en) 2021-08-12
WO2021158660A3 (en) 2021-09-23
IL295258A (en) 2022-10-01
EP4100062A4 (en) 2024-05-22

Similar Documents

Publication Publication Date Title
CN109152798B (zh) 特异于糖基化的pd-1的抗体及其使用方法
CN112533955B (zh) 抗b7-h3抗体
US20190309072A1 (en) Anti-itga3 antibodies, activatable anti-itga3 antibodies, and methods of use thereof
CN111148762A (zh) 免疫特异性结合至btn1a1的抗体和分子及其治疗性用途
CN107530429A (zh) 特异性针对糖基化的pd‑l1的抗体及其使用方法
CA2984945A1 (en) Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereof
KR20150002894A (ko) ｐＨ 의존성 항원 결합을 갖는 항체
US12324936B2 (en) Methods of treating cancer by administering an antibody-drug conjugate targeting human claudin 18.2
US20060228366A1 (en) Tumor specific monoclonal antibodies
US20230146072A1 (en) Anti-gucy2c antibodies and uses thereof
CN110382532A (zh) 抗g-csf抗体及其用途
WO2018067819A1 (en) Compositions and methods for treatment of cancers
TW202342541A (zh) 單域抗Ｎｅｃｔｉｎ－４抗體
JP2024503617A (ja) 抗ｇｐｒｃ５ｄモノクローナル抗体及びその用途
CN114729045B (zh) 对糖基化的ctla-4特异性的抗体及其使用方法
WO2022026775A1 (en) Compositions and methods for targeting coronavirus
US20230236192A1 (en) Anti-hepsin antibodies and uses thereof
TW202409076A (zh) 抗slc34a2單株抗體及其用途
US20250270346A1 (en) Efficacious anti-cd26 antibody biomarker
CN114761042A (zh) Il-38特异性抗体
CN114829404B (zh) 对糖基化的lag3特异的抗体及其使用方法
AU2002365978A1 (en) Tumor specific monoclonal antibodies
CN121443642A (zh) 抗ror1抗体及其用途
HK40126806A (zh) 抗slc34a2单克隆抗体及其用途
HK40080157B (zh) 抗gprc5d单克隆抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240123

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250401

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250530

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250828